The Bench Scale Surface Active Foam Fractionation (SAFF®) Unit is used to Quickly and Cost Effectively Demonstrate PFAS Treatment Performance for Site Specific Water
Allonnia, the bio-ingenuity company dedicated to extracting value where others see waste, today announces new capabilities for bench scale treatability studies for PFAS contaminated sites within their Boston laboratory. The enhanced bench scale capability enables testing of contaminated water samples using SAFF® to determine indicative PFAS removal performance in advance of a full-scale pilot evaluation.
SAFF, created by EPOC Enviro and exclusively distributed in North America by Allonnia, is an elegant solution that uses a natural process to efficiently remove 99.99% of regulated PFAS compounds. It does this without the use of chemicals or adsorption media, yielding a low volume, high density PFAS concentrate for destruction or disposal. The technology has been deployed successfully on three continents, treating tens of millions of gallons of PFAS contaminated water and has proven to be highly effective at addressing PFAS contamination at military bases, landfills and industrial sites.
“The capability to provide bench scale treatability studies for our clients is a big milestone for Allonnia,” said Dayal Saran, VP & Head of Research, Allonnia. “With our laboratory capabilities commissioned, we can successfully prove the efficiency of SAFF and more confidently launch promising pilot studies at each new site.”
Allonnia offers a staged PFAS treatability evaluation process to provide our customers with a reliable and efficient commissioning process. First, the team utilizes a desk-top predictability model, powered by a robust data set developed from years of extensive testing across different water sources from around the world. The predictability model generates a complimentary report detailing anticipated SAFF performance (typically +/- 5%) at the site. The bench scale testing then includes an accurate assessment of removal efficiency and an estimated concentration factor for site specific water. This study also provides SAFF unit set-up parameters for a more efficient and predictable start-up to the third step of a full-scale onsite pilot study.
“Allonnia has the ability to meet the growing market demand for treatability studies enabled by multiple bench scale units to respond to customers’ requests in a timely manner,” said Mack Astorga, VP Business Development, Allonnia. “This ushers in a new chapter for the organization and we’re excited for what’s ahead.”
Allonnia has completed several treatability studies in its Boston lab with the new SAFF bench units, with many more scheduled. These studies are being used to inform pilot studies that started in mid 2022 and will run into the 2023 calendar year.